<code id='9395B506CA'></code><style id='9395B506CA'></style>
    • <acronym id='9395B506CA'></acronym>
      <center id='9395B506CA'><center id='9395B506CA'><tfoot id='9395B506CA'></tfoot></center><abbr id='9395B506CA'><dir id='9395B506CA'><tfoot id='9395B506CA'></tfoot><noframes id='9395B506CA'>

    • <optgroup id='9395B506CA'><strike id='9395B506CA'><sup id='9395B506CA'></sup></strike><code id='9395B506CA'></code></optgroup>
        1. <b id='9395B506CA'><label id='9395B506CA'><select id='9395B506CA'><dt id='9395B506CA'><span id='9395B506CA'></span></dt></select></label></b><u id='9395B506CA'></u>
          <i id='9395B506CA'><strike id='9395B506CA'><tt id='9395B506CA'><pre id='9395B506CA'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:153
          glum Benjamin — health insurance coverage from STAT
          Adobe

          Startup insurers Oscar Health, Bright Health, and Clover Health have hemorrhaged money since going public within the past two years. All three used their stage time at the J.P. Morgan Healthcare Conference to make the case that their drastic decisions — like fully exiting some insurance markets — will deliver the profitability investors are demanding.

          “Insurance company profitability is the number one goal,” Oscar CEO Mario Schlosser said in an interview with STAT in San Francisco.

          advertisement

          “We are actually absolutely focused on profitability right now,” Clover CEO Andrew Toy said during his presentation on Wednesday.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Merck CEO won’t testify in Senate, citing no expertise in drug prices
          Merck CEO won’t testify in Senate, citing no expertise in drug prices

          Sen.BernieSanderstoldreportersthatMerck'sCEOrefusedtotestifyoveralackofexpertiseindrugpricing.Mariam

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Medicare drug price negotiation legal challenge met with skepticism

          AdobeWILMINGTON,Del.—Wednesdaywasthefirsttimethatafederaljudgeaskedquestionsin-personofdrugindustryl